Intervention not reported
Serious adverse events · people at risk for development of T2DM
1 finding from 1 review
Serious adverse events · adults with fibromyalgia
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Serious adverse events · children and adolescents with chronic non‐cancer pain
1 finding from 1 review
Serious adverse events · children (4 to 18 years) with functional abdominal pain disorders
1 finding from 1 review
Serious adverse events · children and adolescents with chronic non‐cancer pain
1 finding from 1 review
Serious adverse events · children and adolescents with chronic non‐cancer pain
1 finding from 1 review
Serious adverse events · children and adolescents with chronic non‐cancer pain
1 finding from 1 review
Intervention not reported
Serious adverse events · people with cancer pain
1 finding from 1 review
Intervention not reported
Serious adverse events · people with cancer pain
1 finding from 1 review
Serious adverse events · Patients with active Crohn's disease
Azathioprine showed no clear difference in serious adverse events compared with infliximab (moderate certainty).
1 finding from 1 review
Serious adverse events · Patients with active Crohn's disease
Azathioprine + infliximab probably leads to lower serious adverse events compared with infliximab (moderate certainty).
1 finding from 1 review
Serious adverse events · Patients with active Crohn's disease
Azathioprine or 6‐mercaptopurine showed no clear difference in serious Adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · adults with GIOP
Bisphosphonates showed no clear difference in serious adverse events compared with control (low certainty).
1 finding from 1 review
Serious adverse events · prevention and treatment of hepatic encephalopathy in people with cirrhosis
Non‐absorbable disaccharides probably leads to lower serious adverse events compared with placebo/no intervention (moderate certainty).
1 finding from 1 review
Serious adverse events · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether lactulose changes serious adverse events compared with lactitol (very low certainty).
1 finding from 1 review
Serious adverse events · patients with maintenance of medically‐induced remission in Crohn's disease
5‐ASA showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · any people undergoing surgery with fluid resuscitation
1 finding from 1 review
Intervention not reported
Serious adverse events · adults with chronic musculoskeletal pain (osteoarthritis)
1 finding from 1 review
no estimate extracted
30 participants
Very low
Serious adverse events · induction of remission in Crohn's disease
Ustekinumab showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · patients aged 0 to 18 years with a diagnosis of functional constipation
PEG showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review